Introduction
Mutation of the tumor suppressor gene p53 occurs in greater than 50% of all human tumors (Hollstein et al., 1994) . In addition, many tumors with wild-type p53 have defects at some other point within the p53 pathway (reviewed in Ko and Prives, 1996; Levine, 1997; Vogelstein et al., 2000) . The p53 gene product is a sequence-specific transcription factor that is activated in response to certain cellular stress signals. These signals include DNA damage (Nelson and Kastan, 1994) , oncogene activation (Lowe and Ruley, 1993) , and hypoxia (Graeber et al., 1996) . Following activation, p53 induces or represses its target genes to produce an appropriate response. One such response essential for the function of p53 as a tumor suppressor is growth suppression. Depending upon the severity of the stress signal, growth suppression may be achieved through cell cycle arrest or apoptosis. Target genes involved in inducing cell cycle arrest include p21 (el-Deiry et al., 1993) , GADD45 ), 14-3-3s (Hermeking et al., 1997 , and MCG10 ; and those involved in inducing apoptosis include Bax (Miyashita and Reed, 1995) , APAF-1 (Robles et al., 2001) , KILLER/DR5 (Wu et al., 1997) , and EphA2 (Dohn et al., 2001a) . p53 may also elicit other responses, including cellular differentiation (Almog and Rotter, 1997) , DNA repair and hence genome stability (Almog and Rotter, 1997) , inhibition of angiogenesis (Dameron et al., 1994; Van Meir et al., 1994) , and tumor surveillance (Zhu et al., 1999) . In these ways, p53 acts as a cellular gatekeeper, preventing proliferation of damaged cells (Levine, 1997) .
Since p53 is so important in regulating cell proliferation, loss of p53 function can lead to the uncontrolled growth characteristic of tumor cells. This explains the prevalence of p53 mutation in human cancer. The most common p53 mutations are missense mutations in the DNA binding domain (DBD) (Hollstein et al., 1994) . As a consequence, mutation of p53 produces a full-length protein that is incapable of binding DNA and is therefore nonfunctional. There are two classes of p53 mutants-conformational mutants and contact site mutants. The conformational mutants, for example, V143A, R249S, and R175H, alter the structure of the protein (Cho et al., 1994) , while the contact site mutants, for example, R248W and R273H, have an altered residue at a site that, in the wild-type protein, directly contacts DNA (Cho et al., 1994; Rolley et al., 1995) . An antibody (Pab 240) that only recognizes the mutant conformation is capable of distinguishing conformational mutants from wild-type protein (Milner and Medcalf, 1991) . Four of the p53 mutations listed above (R249S, R175H, R248W, and R273H) are described as 'hot-spot' mutants because they are among the most prevalent p53 mutations in human cancer (Hollstein et al., 1994) .
A polymorphism of p53 at codon 72 in exon 4 encoding either proline or arginine has been reported to influence the risk for certain types of cancer, including human papillomavirus (HPV)-associated cervical and nonmelanoma skin cancers (Storey et al., 1998; McGregor et al., 2002; Saranath et al., 2002) , and bladder cancer (Soulitzis et al., 2002) . This correlation has been proposed to be due to the increased susceptibility of p53 to degradation by HPV E6 when p53 is homozygous for arginine at codon 72 (Storey et al., 1998) . Despite this reported link, other studies have reported no significant association between cancer risk and the polymorphism at codon 72 (Toruner et al., 2001; Calhoun et al., 2002) . The effect of this polymorphism appears to vary depending on cancer type, stage, and patient population.
In addition to p53, two other members of the p53 family, p63 (Osada et al., 1998; Yang et al., 1998) and p73 (Kaghad et al., 1997) , have been identified. p63 and p73 share significant sequence similarity with p53, particularly in the DBD, activation (AD), and tetramerization (TD) domains (Chen, 1999; Kaelin, 1999; . These two family members are also capable of performing many of the same functions as p53, including induction of cell cycle arrest and apoptosis and, when overexpressed, regulation of many common target genes (Dohn et al., 2001a, b; Jost et al., 1997; Kaghad et al., 1997; Osada et al., 1998; Zhu et al., 1998 Zhu et al., , 1999 . In contrast to p53, however, p63 and p73 have multiple isoforms that differ in the length of their C-termini (Kaelin, 1999; Levrero et al., 2000; . For example, p73a is the fulllength isoform of p73 with 14 exons, while p73b has a truncation at exon 13. There are also DN forms of p63 and p73 which are transcribed from an alternate start site in intron 3 (Yang et al., 1998 . These forms lack the N-terminal activation domain. Of the p73 isoforms, p73b appears to have the highest activity for transactivation of its target genes and suppression of cell growth (Chen, 1999; Irwin and Kaelin, 2001; Moll et al., 2001; Yang et al., 2002) .
Despite the similarities among p53 family members, p63 and p73 have not been found to meet all the requirements for classification as tumor suppressor genes. For example, p73 and p63 are rarely mutated in tumors (Nomoto et al., 1998; Mihara et al., 1999; Yokomizo et al., 1999; Moll et al., 2001) . However, both proteins have been found to play a role in development. Studies in mice have revealed that p63 is important in ectodermal development and keratinocyte differentiation De Laurenzi et al., 2000) . In humans, p63 mutations have been associated with five autosomal dominant inherited syndromes, that is, EEC, AEC, ADULT, limb-mammary syndrome, and nonsyndromic split hand/foot malformation (Celli et al., 1999; Sifakis et al., 2001; Brunner et al., 2002) . The p73 knockout mouse has chronic infections and defects in neural development and pheromone function . The region of chromosome 1 on which p73 is located (1p36) is often deleted in several tumors, including neuroblastoma, melanoma, breast cancer, and colon cancer (Kaghad et al., 1997) . However, few p73 mutations have been detected and wild-type p73 isoforms may actually be overexpressed in some cancers including neuroblastoma (Kovalev et al., 1998; Sunahara et al., 1998; Tannapfel et al., 1999; . Although it is uncertain whether p63 and p73 act as tumor suppressors, these family members appear to regulate the ability of p53 to bind to the promoters of its apoptotic target genes (Flores et al., 2002) . Therefore, these proteins play an important role in assuring that p53 can perform its function as a tumor suppressor.
Since p53 and p73 are highly similar in structure and function, several groups have studied whether mutant p53 and wild-type p73 interact (Di Como et al., 1999; Davison et al., 1999; Marin et al., 2000; Strano et al., 2000; Gaiddon et al., 2001) . These investigators have reported physical associations between p73 isoforms and various p53 mutants. Of these mutants, p53(R175H), a conformational mutant, has consistently been demonstrated to bind to p73 (Di Como et al., 1999; Strano et al., 2000; Gaiddon et al., 2001) . Marin et al. (2000) noticed a correlation between the polymorphism at codon 72 of p53 mutants with their ability to interact physically with wild-type p73. However, this correlation was not observed in studies by Gaiddon et al. (2001) . The physical interaction between p53 mutants and wildtype p73 led to the hypothesis that mutant p53 might influence the ability of p73 to suppress cell growth. In transient cotransfection experiments, this idea has been explored (Di Como et al., 1999; Marin et al., 2000; Strano et al., 2000; Gaiddon et al., 2001) . In these studies, the presence of mutant p53 appears to prevent wild-type p73 isoforms from activating p53 responsive reporters.
In this report, we describe the establishment of stable cell lines capable of inducibly expressing p53 mutants and wild-type p73b concurrently. Using this dualinducible system, we have confirmed that some p53 mutants (R175H and R273H) interact physically with wild-type p73b. Interestingly, in the presence of mutant p53 (V143A, R175H, R248W, R249S, or R273H), p73b retains the ability to transactivate endogenous p21. In addition, mutant p53 does not abrogate the ability of p73b to suppress cell proliferation. This is evident in the ability of p73b to induce both cell cycle arrest and apoptosis in the presence of mutant p53. In this system, there is no effect of the p53 polymorphism at codon 72 on the ability of p73 to suppress cell growth. We also show that the concurrent expression of wild-type p53 and wild-type p73 in the dual inducible system has an additive effect on suppression of cell proliferation.
Results

Dual-inducible system
In order to analyse effectively the relation between wildtype p73 and mutant p53, we have established a system that can inducibly express two gene products. This system is advantageous because it allows exploration of the interaction of two proteins within stable cell lines. The benefits of this system over transient cotransfection assays include better control of levels of protein expression, the ability to analyse the interaction of the proteins over time, and the ability to evaluate, within the p73 is active in the presence of p53 mutants AC Willis et al same cellular background, the activity of either protein alone or both expressed concurrently (Figure 1 ). Using this dual-inducible system, we established stable H1299 cell lines that inducibly express wild-type p73b and one each of the five mutants (V143A, R175H, R248W, R249S, and R273H) (Figure 2 ). In addition, for three of these mutants (V143A, R175H, and R273H), we established one group of cell lines that expresses the mutant with arginine at position 72 and another group that expresses the mutant with proline at position 72. Both proteins, p73b and mutant p53, were tagged with an HA epitope to allow comparison of protein expression levels.
p73b is transcriptionally active in the presence of mutant p53 p21 is a well-characterized transcriptional target of wildtype p53 and induces p53-dependent G1 arrest through the inhibition of cyclin-dependent kinases (el-Deiry et al., 1993) . p73 has also been shown to induce p21 (Jost et al., 1997; Kaghad et al., 1997; Zhu et al., 1998) , although to a lesser extent than p53 (Zhu et al., 1998) . In contrast, the p53 hot-spot mutants are transcriptionally inactive and therefore do not induce p21 (Pietenpol et al., 1994) . In order to determine the transcriptional activity of p73b in the presence of mutant p53, cells were induced to express neither protein, mutant p53 alone, p73b alone, or both concurrently. At 24 h following induction, expression of mutant p53, wild-type p73b, and p21 was evaluated by Western blot analyses. As expected, p73b induced p21 while none of the p53 mutants were active in inducing p21. Interestingly, we found that neither the conformational (V143A, R249S, and R175H) nor the contact site (R273H and R248W) p53 mutants decreased the ability of p73b to induce p21 (Figure 2) . Furthermore, the polymorphism at position 72 had no effect on the ability of p73b to transactivate p21 in the presence of mutant p53 (Figure 2 ). To allay concerns that this lack of suppression might be due to low levels of expression of mutant p53, the cell lines selected for analysis displayed higher levels of mutant p53 protein than wild-type p73b protein (Figure 2 ). Both proteins being tagged with HA facilitate this comparison. Levels of actin are shown as a loading control.
Mutant p53 and wild-type p73b are expressed in the same cells
Although mutant p53 and wild-type p73b expression was selected for in our stable cell lines, we wanted to ensure that these proteins were being expressed within the same cells. This was accomplished using immunofluorescence staining of p53(175)Arg72 and p73b. As shown in Figure 3 , control cells did not stain for p53(175)Arg72 or wild-type p73b; cells induced to express p53(175)Arg72 stained only for p53 (red); cells induced to express p73b stained only for p73 (green); and cells induced to express both proteins stained for both p53 and p73. Therefore, the ability of p73 to Dual Inducible System Figure 1 Dual-inducible system. The dual-inducible system utilizes two inducible expression systems: the tetracycline-repressible system and the ecdysone-inducible system. The tetracycline-repressible system employs the regulatory vector 15-1 neo, which constitutively expresses a chimeric tetracycline transactivator (tTA) composed of a tetracycline repressor fused to the VP16 transactivation domain (Gossen and Bujard, 1992) (reviewed in Saez et al., 1997; Harvey and Caskey, 1998; Rossi and Blau, 1998) . In the presence of tetracycline, tTA is unable to bind to the tetracycline responsive element (TRE) in the expression vector, 10-3, preventing transcription of the gene of interest. However, when tetracycline is removed, tTA binds TRE and induces expression of the gene. In the ecdysone-inducible system (reviewed in Saez et al., 1997; Harvey and Caskey, 1998; Rossi and Blau, 1998) , the regulatory vector pVgRXR constitutively expresses both a modified ecdysone receptor (VgEcR) and the retinoid X receptor. These products form a heterodimer that, in the presence of the ecdysone analog ponasterone A, binds to a hybrid ecdysone/glucocorticoid responsive element in the expression vector (pIND), inducing expression of the gene of interest Figure 3 Mutant p53 and wild-type p73b are expressed in the same cells. Cells were seeded in four-well chamber slides, induced for 24 h in appropriate induction media and stained for p53 and p73. Nuclear stain is blue, p53 stain is red, and p73 stain is green p73 is active in the presence of p53 mutants AC Willis et al transactivate p21 in the presence of mutant p53 occurs when both proteins are expressed within the same cells.
Mutant p53 and wild-type p73b interact physically when both are expressed in the dual-inducible system
Previously, it has been reported that p73b is able to interact with several p53 mutants, including V143A (Marin et al., 2000) , R175H (Strano et al., 2000; Gaiddon et al., 2001) , and R249S (Gaiddon et al., 2001) , both in vitro and in vivo. In order to ensure that the ability of p73 to transactivate p21 in the presence of mutant p53 was not because of a lack of interaction between the proteins, we investigated the physical relationship of these proteins in our system. The interaction between wild-type p73b and the p53 mutants was determined by immunoprecipitation/Western blot analyses. A physical interaction was detected between wild-type p73b and mutant p53(273)Pro72 (Figure 4 , lane 4). In addition, p53(175)Arg72 was also coimmunoprecipitated with p73b (data not shown and Table 1 ). However, immunoprecipitation of p73b revealed no detectable interaction with the other p53 mutants tested (Table 1) . Importantly, the ap73 antibody does not crossreact with p53 (data not shown), and, as expected, cells induced to express only p73b did not precipitate the band corresponding to mutant p53 ( Figure 4 , lane 2). Since both p73b and mutant p53 are HA-tagged, relative amounts of immunoprecipitated protein can be compared.
Mutant p53 does not abrogate the ability of wild-type p73b to inhibit cell proliferation
Since p73b retains its ability to transactivate p21 in the presence of mutant p53, we were interested in evaluating the function of p73 to suppress cell growth in this context. Previously, we and others have demonstrated that p73b is capable of inhibiting cell proliferation (Jost et al., 1997; Kaghad et al., 1997; Zhu et al., 1998) . To examine this activity in the presence of mutant p53, we evaluated the growth rate of cells over 5 days. As shown in Figure 5 , we found that none of the p53 mutants were capable of suppressing cell proliferation as compared to control cells. In contrast, p73b inhibited cell growth completely. In addition, the ability of p73b to inhibit cell proliferation was not diminished upon concurrent expression with any of the p53 mutants, regardless of the residue at codon 72 or the class of mutation (conformational or contact site). In order to confirm that the HA tag did not inhibit the ability of mutant p53 to inactivate p73b, we also established cell lines that express Flag-tagged p73b in the ecdysone-inducible system and one each of the mutants p53(R248W)Pro72, p53(R175H)Arg72, and p53(R249S)Arg72 with no tag. The untagged p53 mutants exhibited the same activity as those that were HA-tagged, that is, they were unable to abrogate the ability of p73b to suppress cell growth (Figure 5h and data not shown).
As shown in Figure 2 , each of the cell lines examined has a higher level of expression of mutant p53 than wildtype p73b. However, to ensure that the inability of p53 mutants to inhibit p73b was not because of excessive expression of p73b, we evaluated the ability of decreasing levels of 73b to transactivate p21 and to suppress cell growth in the presence of constant levels of p53(R175H)Arg72 (Figure 6 ). This particular mutant was chosen because in previous reports, p53(R175H)Arg72 was shown to prevent p73 isoforms from activating p53 responsive reporters (Di Como et al., 1999; Strano et al., 2000; Gaiddon et al., 2001) . As shown in Figure 6a , p73b induced p21 in a dosedependent manner both in the absence and presence of p53(175)Arg72. In Figure 6b , the growth rate of cells over 5 days was determined following induction of neither protein (Control), p53(175)Arg72 alone, p73b alone (induced by increasing concentrations of ponasterone A from 0.33 to 5 mm in the presence of tetracycline), or p53(175)Arg72 þ p73b (induced by Having demonstrated that p53 mutants do not disrupt the function of p73b to inhibit cell growth, we explored the nature of this suppression. We and others have previously shown that p73b is capable of suppressing cell growth through induction of cell cycle arrest and apoptosis Jost et al., 1997; Zhu et al., 1998; Chen, 1999) . In order to determine if p73b retained both of these functions in the presence of mutant p53, we analysed the DNA content, by DNA histogram analysis, of cells induced to express neither protein, mutant p53 alone, wild-type p73b alone, or both proteins concurrently (Figure 7 ). Cell cycle arrest in G1 can be detected by DNA histogram analysis as an increase in the G1 DNA content. The DNA fragmentation characteristic of apoptotic cells can also be detected by DNA histogram analysis as the sub-G1 DNA content. This study revealed an increased G1 DNA content when p73b was expressed, alone or with p53 mutants (Figure 7a and c-h ). In addition, there was an increase in the sub-G1 DNA content in cells expressing wild-type p73b with or without p53 mutants (Figure 7 a-c, f-g). These results are summarized in Table 2 as the percentage of cells in each phase of the cell cycle reported as the mean and standard error of the mean of at least three experiments. The increase in the G1 and sub-G1 DNA content demonstrates that p73b is capable of inducing G1 arrest and apoptosis in the presence or absence of p53 mutants ( Figure 7 and Table 2 ). The differences among cell lines to induce apoptosis or G1 arrest are likely because of differences in expression levels of p73b in various cell lines.
To confirm the induction of apoptosis by p73b in the presence of mutant p53, we performed the trypan blue dye-exclusion assay. As expected, the p53 mutants showed no increase in the percentage of dead cells as compared to control (Figure 8 ). In contrast, cells induced to express p73b had a three-to eight-fold increase in the percentage of dead cells as compared to control (Figure 8 Mutant p53 cannot abrogate the ability of p73b to suppress cell growth. Cells were induced to express neither protein, p53 mutant alone, p73b alone, or both concurrently. Growth rates were evaluated over 5 days as described in Materials and methods p73 is active in the presence of p53 mutants AC Willis et al 1 million) are needed for DNA histogram analysis, the cells used for this assay were plated at higher density than those used for trypan blue analysis. Therefore, the number of living cells expanding exponentially will be greater in the cells used for DNA histogram analysis and produce a decreased percentage of cells detected as apoptotic.
Coexpression of wild-type p53 and p73b additively induces p21 and growth suppression
In addition to the interaction between p53 mutants and wild-type p73b, we were interested in evaluating the concurrent expression of wild-type p53 and p73b. Since the tetracycline-repressible system induces higher expression of protein in our hands than does the ecdysoneinducible system (Figure 9a,b) , we established two groups of cells lines; one that expresses wild-type p53 through the ecdysone-inducible system and wild-type p73b through the tetracycline-repressible system (x112) (Figure 9a ), and the other that expresses wild-type p53 through the tetracycline-repressible system and p73b through the ecdysone-inducible system (x10) (Figure 9b ). Figure 9a ,b showed that both p53 and p73b induced p21. Interestingly, in cell line x112, when both wild-type proteins were expressed concurrently, they induce higher levels of p21 than either protein alone (Figure 9a ). This additive effect was less evident in cell line x10 (Figure 9b ). This is probably because in this cell line, wild-type p53 is expressed under the tetracyclinerepressible system that induces higher levels of protein expression. Therefore, p53 may have already induced the maximum amount of p21 and therefore concurrent expression with p73b cannot further increase this expression. Similar effects were observed when the growth rate of the cell lines was evaluated over 5 days (Figure 9c,d ). In the cell line x112, induction of p53 alone or p73b alone suppressed cell growth, and this suppression was more pronounced when both proteins were expressed concurrently (Figure 9c ). In cell line x10, the effect was less pronounced. This was again likely because of the high level of expression of p53 in the tetracycline-repressible system, resulting in the maximum degree of inhibition of cell proliferation following induction of wild-type p53 alone. The trypan blue dye-exclusion assay demonstrated the additive effect of wild-type p53 and p73b on apoptosis induction in both of these cell lines (Figure 9e,f) . Figure 6 p73b suppresses cell proliferation in a dose-dependent manner in the presence of mutant p53. Varying concentrations of hormone were used to induce p73b in the absence or presence of p53(R175H)Arg72. (a) p73b induces p21 in the absence or presence of mutant p53. Extracts were resolved by SDS-PAGE followed by Western blot with mouse monoclonal a-HA, rabbit polyclonal a-p21, and rabbit polyclonal a-actin. (b) p73b suppresses cell growth in the absence or presence of mutant p53. Growth rate of cells over 5 days was performed as described in Materials and methods
Discussion
Here we report that p73b retains its transactivation function and its ability to suppress cell proliferation through both growth arrest and apoptosis even when the level of mutant p53 expression appreciably exceeds that of p73b. We found no inhibitory effect of mutant p53 on wild-type p73b, regardless of whether the mutant was a member of the conformational or contact site class of mutants. In addition, in our system we detected no functional difference between the activities of p53 mutants with arginine or proline at codon 72. Since Figure 7 p73b can induce cell cycle arrest and apoptosis in the presence of mutant p53. Cells were induced to express neither protein (Control), mutant p53 alone, wild-type p73b alone, or both proteins concurrently (Both) for 72 h. DNA histogram analysis was used to determine the percentage of cells in each phase of the cell cycle as detected by propidium iodide staining of DNA. DNA content was quantified for each cell line at least three times. Representative DNA histograms are shown for each cell line. Please refer to Table 2 for % cell cycle DNA content p73 is active in the presence of p53 mutants AC Willis et al p53 mutation is so prevalent in human tumors, it is exciting that overexpression of one of the p53 family members can suppress the growth of cancer cells that harbor mutant p53. The dual-inducible system allows inducible expression of mutant p53 and wild-type p73b, either alone or concurrently, within stable cell lines. This system allows us to control tightly the levels of protein expression and to evaluate the activity of each protein alone and together in the context of the same cellular background and over time. Previous reports have indicated that, in transient cotransfection experiments, certain p53 mutants have the ability to inhibit the activity of wild-type p73 to transactivate p53 responsive reporters (Di Como et al., 1999; Marin et al., 2000; Strano et al., 2000; Gaiddon et al., 2001) . The apparent discrepancy between these results and ours is likely because of the inability to control levels of protein expression in transient transfection experiments. In fact, to confirm that we could reproduce the results obtained , we transiently cotransfected wild-type p73b and p53(R175H)Arg72 with a luciferase reporter under the control of the p21 basic promoter that has two p53 responsive elements (Chinery et al., 1997) . In these assays, p53(175) did reduce the ability of p73b to activate the p21 reporter (data not shown). However, the dual-inducible system provides a more physiological environment for analysis of the interaction of these proteins. For example, we were able to evaluate the transactivation of endogenous p21 rather than a p53 responsive reporter. We were also able to explore the effect of protein expression on the cells over time in growth rate assays performed over 5 days. In this way, we have shown that mutant p53 does not abrogate the ability of wild-type p73b to suppress cell proliferation.
Previously, several groups have explored the physical interaction between mutant p53 and wild-type p73 expressed both exogenously and endogenously. These experiments and data reported here (Figure 4 and Strano et al., 2000; Gaiddon et al., 2001) . The heterotetramer formed in this interaction likely consists of a dimer of mutant p53 and a dimer of wild-type p73b. According to a recent report, p53 forms dimers cotranslationally (Nicholls et al., 2002) , indicating that the protein dimer of mutant p53 is formed before it encounters the p73b protein. Therefore, the stoichiometry of the heterotetramer is two molecules of p73 and two molecules of mutant p53. If mutant p53 and wildtype p73b were produced in the same amounts and had equal affinity for formation of heterotetramers as homotetramers, we would expect 25% mutant p53 homotetramers, 25% wild-type p73b homotetramers, and 50% heterotetramers. However, as mentioned above, mutant p53 expression is higher than that of p73b. In addition, mutant p53 and wild-type p73 have been reported to interact through their DBDs but not through their oligomerization domains (Davison et al., 1999; Strano et al., 2000; Gaiddon et al., 2001) . Since the affinity between the two tetramerization domains from the identical p53 or p73 dimers is much higher than that between the DBDs from one p53 dimer and one p73 dimer (Davison et al., 1999) , the mutant p53/wild-type p73 heterotetramer would be far less stable than the homotetramer of mutant p53 or wild-type p73. For this reason, we expect the percentage of mutant p53/wildtype p73b heterotetramers to be far lower than 50%. This is indeed what we have found (Figure 4 ).
It is intriguing that p73 retains its function while physically interacting with mutant p53. This may be because of the nature of the interaction between wildtype p73 and the p53 mutants. Perhaps this interaction does not interfere with the binding of DNA by p73. It has been proposed that when p53 mutants interact with wild-type p53, they alter the wild-type protein to assume the mutant conformation (Milner and Medcalf, 1991; Brachmann et al., 1996; Chene, 1998) . Perhaps a similar alteration occurs when mutant p53 and wild-type p73 interact, except that mutant p53 does not alter the DNA binding ability of wild-type p73. Alternatively, the interaction between mutant p53 and wild-type p73b may be so unstable and transient that mutant p53 is unable to affect p73b activity. The true nature of this interaction poses many questions and leaves much to be explored.
It has been proposed previously that the identity of the codon at position 72 of mutant p53 affects its ability to inhibit wild-type p73. As mentioned above, we found no effect of the polymorphism at codon 72 on the ability of p73b to suppress cell growth. In addition, we found no correlation between the identity of the codon at position 72 and the ability of wild-type p73b to interact physically with mutant p53. The effect of this polymorphism on the physical interaction between p53 mutants and wild-type p73 is also uncertain in previous reports. While Marin et al. (2000) found a positive correlation between arginine at position 72 and the interaction of mutant p53 with wild-type simian p73, Gaiddon et al. (2001) found that two of the three mutants that interacted best with human p73 had a proline at codon 72. In addition to our experiments with mutant p53 and wild-type p73b, we also established stable cell lines expressing wild-type p53 and wild-type p73b. An analysis of these cell lines reveals that wild-type p53 and p73b, when overexpressed, cooperated to induce transactivation of p21 and to suppress cell growth. The dual-inducible system is ideal for allowing exploration of the interaction between these proteins.
We would like to note that the ability of wild-type p73b to suppress cell proliferation in the presence of mutant p53 has potential clinical implications. The majority of human cancers have a mutation in p53 Figure 9 Wild-type p53 and p73b cooperate to transactivate p21, suppress cell proliferation, and induce apoptosis. (a,b) Cells were induced to express neither protein (lane 1), wild-type p53 alone (lane 2), p73b alone (lane 3), or both proteins concurrently (lane 4) for 24 h. Cell extracts were collected and proteins were resolved by SDS-PAGE. HA-tagged p73b and p53 were detected by probing with an aHA antibody. p21 expression was detected with the polyclonal antibody ap21 (C19). The membrane was probed with actin as a loading control. (c,d) Cells were induced to express neither protein, wild-type p53 alone, p73b alone, or both concurrently. Growth rates were evaluated over 5 days as described in Materials and methods. (e,f) Cells were seeded at approximately 60 000 cells/60 mm plate and treated with the appropriate induction media for 72 h. Trypan blue dye-exclusion assay was performed to determine the percentage of dead cells p73 is active in the presence of p53 mutants AC Willis et al (Hollstein et al., 1994) . The ability of p73 to suppress cell proliferation in the presence of mutant p53 could provide ideas for alternative cancer therapies. For example, overexpression of a functional wild-type p73 in tumors could suppress their growth and elicit a clinical response. In fact, adenoviral vectors have been used to deliver p73 to tumor cells that are resistant to treatment by wild-type p53 (Shinoura et al., 2000; Sasaki et al., 2001) . The therapeutic potential of p73 remains to be explored, but the data reported here indicate that this protein could be useful in treating for cancers with mutant p53.
Materials and methods
Plasmids
p53 was tagged with an influenza HA tag as previously described and cloned into a tetracyclinerepressible expression vector, pUHD 10-3, at its EcoRI site and into an ecdysone-inducible expression vector, pIND (Invitrogen, Carlsbad, CA, USA), at its EcoRI site. p53 mutants (V143A with Pro72, R175H with Arg72, R248S with Pro72, R249W with Arg72, and R273H with Arg72) were excised from pCMV-143, pCMV-175, pCMV-248, pCMV-249, and pCMV-273, respectively (kindly provided by Bert Vogelstein) and cloned into pUHD 10-3 at its BamHI sites to produce 10-3 expression vectors containing p53(143)Pro72, p53(175)Arg72, p53(248)Pro72, p53(249)Arg72, and p53(273)-Arg72, respectively. To make HA-tagged p53(175)Pro72, p53(273)Pro72, and p53(248)Pro72, the N-terminal region (residues 2-143: PvuII site) of the HA-tagged wild-type p53 was used to substitute the corresponding region in mutant p53. To make HA-tagged p53(175)Arg72, the N-terminal region (residues 2-39: BsrDI site) of HA-tagged wild-type p53 was used to substitute the corresponding region in p53(175)Arg72. To make HA-tagged p53(273)Arg72 and p53(249)Arg72, the region of the HA-tagged construct (p53(175)Arg72) with arginine at codon 72 (residues 2-143: PvuII site) was used to substitute the region of mutant constructs containing proline at codon 72. To make HA-tagged p53(143)Arg72, the region of the HA-tagged construct (p53(175)Arg72) with arginine at codon 72 (residues 2-124: BsaAI site) was used to substitute the N-terminal region of p53(143). To make p53(143)Pro72, the N-terminal region (residues 2-124: BsaAI site) of HAtagged wild-type p53 was used to substitute the corresponding region in p53(143).
Human Flag-tagged p73b was generated by RT-PCR using 5 0 primer, p73-5 (ATGTCGACGCCACCATGGATTA-CAAGGATGACGACGATAAGGCCCAGTCCACCGCC-ACCTCC) and 3'primer, p73-3 (GGTGTTGGAGGGGAT-GACAGG). The p73 cDNA was cloned into the TA cloning vector pGEM-T Easy (Promega Corporation, Madison, WI, USA) and sequenced to confirm its identity. Flag-p73b was then cloned into pIND at its KpnI and BamHI sites. Human HA-tagged p73b was generated by PCR using 5 0 primer, p73HA (AAGGATCCACCATGTACCCATACGATGTTC-CAGATTACGCTGCCCAGTCCACCGCCACC) and 3 0 primer, p73-3. HA-p73b was then cloned into pUHD 10-3 (at its BamHI site) and into pIND (at its BamHI site).
Cell culture
H1299 is a p53-null human nonsmall cell lung carcinoma cell line. Cells were cultured in Dulbecco's modified Eagle's medium (Gibco, Invitrogen Corp., Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (Gibco, Invitrogen Corp., Carlsbad, CA, USA). All inductions were cultured in Dulbecco's modified Eagle's medium with 10% tet-systemapproved serum (BD Biosciences Clonetech, Palo Alto, CA, USA). Cells were grown at 371C with 5% CO 2 and split as needed with 0.25% trypsin-1 mm EDTA (Gibco, Invitrogen Corp., Carlsbad, CA, USA).
Establishment of a dual-inducible system and stable cell lines All transfections were achieved using the calcium phosphate method as previously described (Chen and Okayama, 1987) . H1299 cells were transfected with the tetracycline-repressible system regulatory vector,15-1 neo and selected with 500 mg/ml neomycin (G418) to establish H24 cells as previously described (Chen et al., 1996) . These cells were subsequently transfected with the ecdysone-inducible system regulatory vector, pVgRXR and selected with zeocin (250 mg/ml) to establish HTE20 cells. To establish stable cell lines, HTE20 cells were cotransfected with three plasmids: (1) pBabe (Morgenstern and Land, 1990) , (2) a 10-3 vector containing either wild-type p53, one of the p53 mutants, or wild-type p73b, and (3) a pIND vector containing wild-type p73b or wild-type p53 (Figure 1 ). Cells were selected with 1 mg/ml puromycin (Sigma Chemical Co., St Louis, MO, USA). Individual clones were screened for inducible expression of wild-type or mutant p53 and for wildtype p73 by Western analyses using an anti-HA antibody (see below). The established cell lines are as follows: p53/p73b x10 inducibly expresses wild-type p53 in the tetracycline-repressible system and wild-type p73b in the ecdysone-inducible system; p53/p73b x112 inducibly expresses wild-type p53 in the ecdysone-inducible system and wild-type p73b in the tetrepressible system. The following cell lines express mutant p53 in the tetracycline-repressible system and p73b in the ecdysoneinducible system: p53(143)Pro72/p73b x605 inducibly expresses p53(143)Pro72 and p73b; p53(143)Arg72/p73b x910 and x916 inducibly express p53(143)Arg72 and p73b; p53(175)Pro72/p73b x726 inducibly expresses p53(175)Pro72 and p73b; p53(175)Arg72/p73b x405 and x406 inducibly express p53(175)Arg72 and p73b; p53(249)Arg72/p73b x208 inducibly expresses p53(249)Arg72 and p73b; p53(273)Pro72/ p73b x306 inducibly expresses p53(273)Pro72 and p73b; p53(273)Arg72/p73b x506 inducibly expresses p53(273)Arg72 and p73b; and p53(248)Pro72/p73b x802 and x11 inducibly express p53(248)Pro and p73b. p53 and p73 proteins in all cell lines were HA-tagged except for p53(248)Pro72/p73b x11, which expresses Flag-tagged p73b and untagged p53(248)-Pro72.
Western analyses
To extract protein, cells were washed with 1 Â phosphatebuffered saline (PBS: 8 g NaCl, 0.2 g. KCl, 1.44 g Na 2 HPO 4 , and 0.24 g KH 2 PO 4 in 1 l as described in Sambrook et al., 1989) , resuspended in 2 Â sample buffer, and denatured by boiling for 5 min. Western analyses were performed as previously described (Chen et al., 1996) . Briefly, proteins were resolved by 10% SDS-PAGE and transferred to nitrocellulose membrane. Anti-HA antibody 12CA5 mouse monoclonal antibody was purchased from Roche Molecular Biochemicals (Indianapolis, IN, USA). Anti-p21 polyclonal antibody C19 was purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Anti-actin polyclonal antibody was purchased from Sigma Chemical Co. (St Louis, MO, USA).
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Immunofluorescence
Cells were seeded at approximately 60% confluency on fourwell chamber slides and induced to express neither protein (2 mg/ml tetracycline, no ponasterone), mutant p53 alone (no tetracycline, no ponasterone), wild-type p73b alone (2 mg/ml tetracycline, 5 mm ponasterone), or both proteins concurrently (no tetracycline, 5 mm ponasterone). At 24 h after induction, cells were fixed with 10% formalin in PBS, permeabilized with 1% NP-40, and blocked with 15% goat serum (Sigma Chemical Co., St Louis, MO, USA). Fixed cells were incubated for 60 min with the primary antibodies, rabbit ap53 (Geneka Biotechnology, Inc., Montre´al, Que´bec, Canada), and mouse monoclonal ap73 (Ab3, Oncogene Research Products, San Diego, CA, USA). Cells were then stained for 30 min with the secondary antibodies, Texas Red-conjugated goat anti-rabbit (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA) and FITC-conjugated goat anti-mouse (Jackson ImmunoResearch Laboratories, Inc., West Grove, PA, USA). Nuclei were visualized by staining with 4 0 ,6-diamidino-2-phenylindole (DAPI) (Molecular Probes, Inc., Eugene, OR, USA) and mounted with cover slips. Stained cells were analysed by fluorescent microscopy.
Immunoprecipitation
Subconfluent cells were induced to express both mutant p53 and wild-type p73b by removal of tetracycline and addition of 3 mm ponasterone, respectively. At 24 h after induction, plates were placed on ice and washed two times with 1 Â PBS. Cells were then collected by scraping and resuspended in 1% NP-40 lysis buffer (20 mm Tris-HCl pH 8.0, 0.2 mm EDTA, 150 mm NaCl and 1% Nonidet P-40) with protease inhibitors (8.5 mg/ml aprotinin, 5 mg/ml leupeptin, 5 mg/ml pepstatin, 1 mm DTT, and 1 mm PMSF) on ice for 15 min. Lysates were freeze-thawed three times and clarified by centrifugation. Samples were precleared with zysorbin (Zymed Technologies, South San Fransisco, CA, USA) for at least 1 h at 41C. p73 was immunoprecipitated with 10 ml of anti-p73 antibody (Ab2; Oncogene Research Products, San Diego, CA, USA) and 40 ml of 50% protein A sepharose beads (Sigma Chemical Co., St Louis, MO, USA) to precipitate the antigen-antibody complex. The immunoprecipitate was then washed three times in 1% NP-40 lysis buffer and resuspended in 2 Â SDS-PAGE loading buffer and denatured by boiling for 3 min. Proteins were resolved by 10% SDS-PAGE, transferred to nitrocellulose, and probed for mutant p53 and wild-type p73 with anti-HA monoclonal antibody (12CA5, Roche Molecular Biochemicals, Indianapolis, IN, USA).
Growth rate analyses
Cells were seeded at approximately 60 000 cells/60-mm plate. Cells were induced to express neither protein, mutant p53 alone, wild-type p73b alone, or both proteins concurrently. Medium was replaced every 72 h. Each day over 5 days, two plates for each of the four inductions were washed with DMEM to remove dead cells. Live cells were trypsinized and samples from each plate were counted three times using a Coulter cell Counter (Coulter Corporation, Miami, FL, USA). The average number of cells from each plate was calculated to determine the growth rate for each induction.
Trypan blue dye exclusion
Cells were seeded at approximately 60 000 cells/60-mm plate. Cells were induced to express neither protein, mutant p53 alone, wild-type p73b alone, or both proteins concurrently. At 3 days following induction, live and dead cells were collected from three plates separately for each induction. Cells were stained for 15 min with 0.4% Trypan blue dye solution (Sigma Chemical Co., St Louis, MO, USA) and counted using a hemocytometer. The percentage of dead cells (stained)/total cells was determined by counting an average of 200-800 total cells, two times for each plate.
DNA histogram analysis
Cells were seeded at approximately 200 000 cells/100-mm plate and induced to express neither protein, mutant p53 alone, wild-type p73b alone, or both proteins concurrently. At 3 days after induction, both floating cells in the medium and live cells on the plate were collected and fixed with 100% ethanol for at least 1 h at 41C. The fixed cells were centrifuged and resuspended at a concentration of 2 million cells/ml in 1 Â PBS with 20 mg/ml of RNase A (Sigma Chemical Co., St Louis, MO, USA) and 50 mg/ml of propidium iodide (Sigma Chemical Co., St Louis, MO, USA). The stained cells were analysed in a fluorescence-activated cell sorter (FACSCaliber; Becton Dickson, Menlo Park, CA, USA) within 4 h.
